Earnings Summary

ZEALAND PHARMA A/S-ADR’s revenue fell -68.47% since last year same period to $15.08Mn in the Q1 2022. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -72.09% fall in its revenue since last 3-months.

ZEALAND PHARMA A/S-ADR’s net profit jumped 7.99% since last year same period to $-222.85Mn in the Q1 2022. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated 20.49% jump in its net profits since last 3-months.

ZEALAND PHARMA A/S-ADR’s net profit margin fell -191.84% since last year same period to -1478.05% in the Q1 2022. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -184.86% fall in its net profit margins since last 3-months.

ZEALAND PHARMA A/S-ADR’s earning per share (EPS) estimates for the current quarter stand at -6.61 - a -3.44% fall from last quarter’s estimates.

ZEALAND PHARMA A/S-ADR’s earning per share (EPS) estimates for the current year stand at -6.61.

ZEALAND PHARMA A/S-ADR’s earning per share (EPS) jumped 10.73% since last year same period to -5.16 in the Q1 2022. This indicates that the ZEALAND PHARMA A/S-ADR has generated 10.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ZEALAND PHARMA A/S-ADR’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ZEALAND PHARMA A/S-ADR’s return on equity (ROE) stands at -0.94.